Entera Bio (NASDAQ:ENTX) Director Geno Germano Purchases 20,000 Shares

Entera Bio Ltd. (NASDAQ:ENTX) Director Geno Germano bought 20,000 shares of the firm’s stock in a transaction that occurred on Monday, March 9th. The shares were acquired at an average price of $1.30 per share, with a total value of $26,000.00. Following the purchase, the director owned 40,000 shares of the company’s stock, valued at $52,000. The trade was a 100.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Entera Bio Trading Up 4.4%

Shares of NASDAQ ENTX traded up $0.07 during mid-day trading on Wednesday, reaching $1.56. The company had a trading volume of 24,424 shares, compared to its average volume of 211,615. The firm has a 50 day simple moving average of $1.49 and a two-hundred day simple moving average of $1.96. Entera Bio Ltd. has a 52-week low of $1.00 and a 52-week high of $3.22. The stock has a market cap of $71.31 million, a P/E ratio of -6.22 and a beta of 1.83.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Superstring Capital Management LP acquired a new stake in shares of Entera Bio during the fourth quarter valued at about $33,000. Citadel Advisors LLC raised its holdings in shares of Entera Bio by 243.0% during the third quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock worth $77,000 after purchasing an additional 28,322 shares during the period. HighTower Advisors LLC lifted its holdings in Entera Bio by 137.8% in the fourth quarter. HighTower Advisors LLC now owns 43,140 shares of the company’s stock worth $84,000 after acquiring an additional 25,000 shares during the last quarter. Jane Street Group LLC boosted its position in Entera Bio by 142.6% during the 4th quarter. Jane Street Group LLC now owns 74,064 shares of the company’s stock valued at $144,000 after purchasing an additional 43,536 shares during the period. Finally, Renaissance Technologies LLC boosted its holdings in shares of Entera Bio by 22.2% during the fourth quarter. Renaissance Technologies LLC now owns 108,001 shares of the company’s stock valued at $210,000 after acquiring an additional 19,601 shares during the period. Hedge funds and other institutional investors own 14.11% of the company’s stock.

Wall Street Analysts Forecast Growth

ENTX has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Entera Bio in a report on Monday, February 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Entera Bio in a research note on Thursday, January 22nd. Finally, Wall Street Zen upgraded Entera Bio to a “sell” rating in a research report on Saturday, December 27th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Entera Bio has an average rating of “Hold” and a consensus price target of $10.00.

Entera Bio Company Profile

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.